Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Comparative characteristics of patients with different types of Alport syndrome inheritance
https://doi.org/10.21508/1027-4065-2022-67-2-43-50
Abstract
Purpose. A comparative characterization of clinical forms and outcomes in patients with Alport syndrome with different types of inheritance.
Characteristics of patients and research methods. We have conducted a retrospective controlled comparative non-randomized single-center longitudinal study that included 60 patients who were admitted to nephrology department of the Russian Children’s Clinical Hospital of the Pirogov Russian National Research Medical University from 2004 to 2020: there were 22 (37%) girls and 38 (63%) boys from 2 to 18 years of age. The median age (Me) was 8,7 [5,4; 13,7] years old. The patients were divided into 2 groups: Group 1 received with cyclosporine A and nephroprotectors, Group 2 received nephroprotectors only.
Results. We identified 75% X-linked, 20% autosomalrecessive, and 5% autosomal dominant types of inheritance among our patients. 45% manifested with combined hematuria with proteinuria, 43% of patients — with isolated hematuria, and 12% — with isolated proteinuria. Hearing damage was detected in 45% of patients, eye damage — in 5%. Nephrotic syndrome developed in 22% of patients, arterial hypertension — in 15%. In patients with X-linked Alportsyndrome, there was a statistically significant(p=0,002) reduction of proteinuria during the first 6 months of treatment in Group 1 compared to Group 2. The difference in proteinuria decrease during therapy is not statistically significant among differenttypes of inheritance. According to survival data, patients with autosomalrecessive inheritance of disease proceed more severely in comparison with other types of inheritance, and this difference tendsto be statically significant(p=0,065).
Conclusion. Timely diagnosis and proper management of patients with Alport syndrome can improve the disease outcome. To determine the prognosis, it is important not only to collect detailed patient’s history and conduct morphological examination, but also to provide genetic testing to determine the type of inheritance.
About the Authors
K. V. Shebalkina
Russian Children’s Clinical Hospital of Pirogov Russian National Research Medical University; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
E. K. Petrosyan
Russian Children’s Clinical Hospital of Pirogov Russian National Research Medical University; Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
P. V. Shumilov
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow
References
1. Ignatova M.S., Dlin V.V. Hereditary kidney diseases with hematuria. Rossiyskiy vestnik perinatologii i pediatrii 2014; 59(3): 82–90. (in Russ.)
2. Veltischev Yu.E., Ignatova M.S. Prophylactic and preventive nephrology (genetic and pathological factors of the development of nephropathies). M., 1996; 61. (in Russ.)
3. Nozu K., Nakanishi K., Abe Y., Udagawa T., Okada S., Okamoto T. et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol 2019; 23(2): 158–168. DOI: 10,1007/s10157–018–1629–4
4. Lemmink H.H., Schröder C.H., Monnens L.A., Smeets H.J. The clinical spectrum of type IV collagen mutations. Hum Mutat 1997; 9(6): 477–499. DOI: 10,1002/(SICI)1098–1004(1997)9:6<477::AID-HUMU1>3,0.CO;2-#
5. Sigmundsson T.S., Palsson R., Hardarson S., Edvardsson V. Resolution of proteinuria in a patient with X-linked Alport syndrome treated with cyclosporine. Scand J Urol Nephrol 2006; 40(6): 522–525. DOI: 10,1080/00365590600830417
6. Heidet L., Gubler M.C. Syndrome d’Alport: néphropathie héréditaire associée à des mutations dans les gènes codant les chaînes de collagène de type IV [Alport syndrome: Hereditary nephropathy associated with mutations in genes coding for type IV collagen chains]. Nephrol Ther 2016; 12(7): 544–551. French. DOI: 10,1016/j.nephro.2016.09.001
7. Charbit M., Gubler M.C., Dechaux M., Gagnadoux M.F., Grünfeld J.P., Niaudet P. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 2007; 22(1): 57–63. DOI: 10,1007/s00467–006–0227-y
8. Gross O., Tönshoff B., Weber L.T., Pape L., Latta K., Fehrenbach H. et al; German Pediatric Nephrology (GPN) Study Group and EARLY PRO-TECT Alport Investigators. A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport’s syndrome. Kidney Int 2020; 97(6): 1275–1286. DOI: 10,1016/j.kint.2019.12.015
9. Dlin V.V., Ignatova M.S., Konkova N.E. Clinical guidelines for the diagnosis and treatment of Alport syndrome in children. Nefrologiya 2015; 19(3): 86–89 (in Russ.)]
10. Yamamura T., Nozu K., Fu X.J., Nozu Y., Ye M.J., Shono A. et al. Natural History and Genotype-Phenotype Correlation in Female X-Linked Alport Syndrome. Kidney Int Rep 2017; 2(5): 850–855. DOI: 10,1016/j.ekir.2017.04.011
11. Jais J.P., Knebelmann B., Giatras I., Marchi M., Rizzoni G., Renieri A. et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol 2000; 11(4): 649–657. DOI: 10,1681/ASN.V114649
12. Torra R., Furlano M. New therapeutic options for Alport syndrome. Nephrol Dial Transplant 2019; 34(8): 1272–1279. DOI: 10,1093/ndt/gfz131
13. Savige J., Sheth S., Leys A., Nicholson A., Mack H.G., Colville D. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol 2015; 10(4): 703–709. DOI: 10,2215/CJN.10581014
14. Oka M., Nozu K., Kaito H., Fu X.J., Nakanishi K., Hashimura Y. et al. Natural history of genetically proven autosomal recessive Alport syndrome. Pediatr Nephrol 2014; 29(9): 1535– 1544. DOI: 10,1007/s00467–014–2797–4
15. Storey H., Savige J., Sivakumar V., Abbs S., Flinter F.A. COL4A3/ COL4A4 mutations and features in individuals with autosomal recessive Alport syndrome. J Am Soc Nephrol 2013; 24(12): 1945–1954. DOI: 10,1681/ASN.2012100985
16. Callís L., Vila A., Nieto J., Fortuny G. Effect of cyclosporin A on proteinuria in patients with Alport’s syndrome. Pediatr Nephrol 1992; 6(2): 140–144. DOI: 10,1007/BF00866293
17. Callís L., Vila A., Carrera M., Nieto J. Long-term effects of cyclosporine A in Alport’s syndrome. Kidney Int 1999; 55(3): 1051–1056. DOI: 10,1046/j.1523–1755,1999,0550031051.x
18. Massella L., Muda A.O., Legato A., Di Zazzo G., Giannakakis K., Emma F. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience. Pediatr Nephrol 2010; 25(7): 1269–1275. DOI: 10,1007/s00467–010–1484–3
Review
For citations:
Shebalkina K.V., Petrosyan E.K., Shumilov P.V. Comparative characteristics of patients with different types of Alport syndrome inheritance. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2022;67(2):43-50. (In Russ.) https://doi.org/10.21508/1027-4065-2022-67-2-43-50
Views:
584
Email this article 